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Chapter pages in book: (191 - 222)Disability among the elderly has declined markedly in the United States
in the past two decades. In 1984, 25 percent of the elderly population re-
ported diﬃculty with activities associated with independent living.1By 2004
and 2005, the share had fallen to below 20 percent, a decline of one ﬁfth.
Although these basic facts are well known, the interpretation of these
facts is not clear. Is the reduction in disability a result of improved medical
care, individual behavioral changes, or environmental modiﬁcations that
allow the elderly to better function by themselves? Will the trend continue,
or is it time limited? What does the reduction in disability mean for years
of healthy life and labor force participation? We explore these issues in this
chapter.
To make progress, we focus on disability caused by a speciﬁc set of med-
ical conditions—cardiovascular disease. Focusing on one condition is help-
ful because it allows us to analyze health shocks and their sequelae in some
detail. Cardiovascular disease (CVD) is a natural condition to pick because
it is the most common cause of death in the U.S. (and most other developed
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1. The data are from the National Long-Term Care Survey, a survey we describe later and
use in this chapter.countries), and more is spent on cardiovascular disease than any other con-
dition. Thus, this is a case where medical care could really matter.
Our analysis has three parts. In the ﬁrst part, we examine basic trends in
disability associated with cardiovascular disease. We show that reduced
disability for people with cardiovascular disease incidents is a major part
of reductions in overall disability, accounting for between one ﬁfth and one
third of the total reduction in disability. The second part of the chapter
considers the role of advances in medical care in reducing disability from
cardiovascular disease. We show that medical technology in the treatment
of cardiovascular disease is a major factor in reduced disability. We esti-
mate that use of recommended treatments for heart attacks, including pre-
scriptions of beta-blockers, aspirin, and ace-inhibitors at discharge, as well
as use of reperfusion and other surgical procedures may have increased the
probability that elderly patients survive an acute cardiovascular event in a
nondisabled state by up to 50 percent between 1984 and 1994. The third
part of the chapter considers the long-run health and ﬁnancial impacts of
improved care for people with cardiovascular disease.
6.1 Background on Cardiovascular Disease
Cardiovascular diseases are diseases of the heart and blood vessels,
which carry oxygen to the body’s major organs. Ischemic heart disease is
the most common manifestation of cardiovascular disease. When the ar-
teries supplying blood to the heart become occluded, the heart does not get
enough oxygen. Like any muscle, oxygen is essential for the heart’s perfor-
mance. Constriction of the coronary arteries will result in chest pain on ex-
ertion, or perhaps at rest. A person with such constriction might be unable
to engage in activities such as walking for a prolonged period (for example,
to get to a grocery store) or engaging in light or heavy housework (clean-
ing, cooking, etc.)
A blockage of the arteries to some or all of the heart is termed a my-
ocardial infarction, or heart attack. The equivalent in other extremities, es-
pecially the legs, is termed peripheral vascular disease. Heart attacks can be
fatal and can lead to substantial disability if survived. A person who sur-
vives a heart attack might be unable to shop or cook, might have diﬃculty
walking up stairs or entering a raised bathtub, and might have diﬃculty
keeping house. Peripheral vascular disease can lead to the same types of
impairments.
Medical advances have made tremendous strides in preventing and
treating coronary events. Several risk factors for heart disease are well
known. Traditional risk factors include smoking, hypertension or high
blood pressure, high cholesterol, obesity, family history, age, and diabetes.
Since the early 1970s, standard recommendations for people at risk have
been behavioral changes (stop smoking, reduce weight, cut back on fat in-
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ication, and more recently, cholesterol-reducing medications). Cutler and
Kadiyala (2003) show signiﬁcant reductions in the incidence of heart dis-
ease over time attributable to reductions in these risk factors, especially re-
duced smoking and better blood pressure control.
There have also been technological changes in the treatment available
for people with severe heart disease. Bed rest was once standard therapy for
people with heart attacks. Today, therapy for a heart attack—and often
heart disease in earlier stages of progression—generally starts with drugs
such as aspirin, which help dissolve clots and restore blood ﬂow to the
heart. Beta-blockers are also given to reduce the workload of the heart and
thus reduce the demand for oxygen. In addition, ace-inhibitors are pre-
scribed to help reduce the workload of the heart by lowering blood pres-
sure. Statins are prescribed to help process and break down cholesterol in
the arteries (American Heart Association 2006).
Finally, there have been signiﬁcant advances in acute care and invasive
surgical procedures for treating coronary blockage. Thrombolytics are a
class of drugs that may be used to help dissolve the clot. Percutaneous coro-
nary intervention (PCI) is used to clear out blockages of the coronary ar-
teries. These procedures are now frequently accompanied by use of a stent
to keep the occluded artery open. A more invasive option is coronary artery
bypass grafting (abbreviated CABG, and pronounced like the vegetable).
Each of these technologies has been shown to increase survival after 
a heart attack among patients without contraindications for treatment
(Krumholz et al. 1995; Hennekens et al. 1996; Krumholz et al. 1996;
Soumerai et al. 1997; Gottlieb, McCarter, and Vogel 1998; Krumholz et al.
1998; Freemantle et al. 1999; Shlipak et al. 2001; Braunwald et al. 2002;
Antman et al. 2004; Vitagliano et al. 2004; Stukel, Lucas, and Wennberg
2005). They have an ambiguous eﬀect on disability, however, with the in-
crease in survival among those with serious heart damage possibly oﬀset-
ting the improved health among traditional survivors (Crimmins, Saito,
and Ingegneri 1989; Crimmins, Hayward, and Saito 1994; Waidmann,
Bound, and Schoenbaum 1995).
Cerebrovascular disease, or stroke, is the second major form of cardio-
vascular disease. Ischemic strokes are the most common type of stroke and
are similar to heart disease: an artery in the brain becomes blocked, and 
a part of the brain is denied oxygen. Disability is quite common after a
stroke, particularly among the elderly (Pohjasvaara et al. 1997; Prencipe 
et al. 1997; Zhu et al. 1998). Recent studies report that 39 percent to 54 per-
cent of stroke survivors are disabled three months after the stroke (Henon
et al. 1995; Zhu et al. 1998; Glader et al. 2003). The high level of disability
can persist among survivors. One study found that 37 percent of stroke
survivors were disabled one year after the event (Appelros, Nydevik, and
Viitanen 2003). In addition, stroke is associated with increased odds of
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1997; Prencipe et al. 1997; Zhu et al. 1998).
Thrombolytic medication may be given after a stroke, but the beneﬁt is
far less certain than in heart disease. Clinical trials show that thrombolytics
are eﬀective only if given in the ﬁrst three hours after an acute event (Na-
tional Institute of Neurological Disorders, 1995; Clark et al. 1999; Adams
et al. 2005). Revascularization procedures such as carotid endarterectomy
may be performed in patients with certain types of stroke—including tran-
sient ischemic attacks—after the patients have recovered from the acute
phase of the stroke. A small share of strokes are hemorrhagic strokes, where
a blood vessel bursts and there is bleeding in the skull. Little therapy is gen-
erally available in such cases, and death is common.
Heart failure and arrhythmias are other types of cardiovascular disease
that cause substantial morbidity and mortality among the elderly. Heart
failure occurs when the heart’s ability to pump blood is impaired. Patients
may experience breathlessness and fatigue that makes it diﬃcult to keep up
usual activities, ﬂuid retention and edema, coughing, memory loss, and
heart palpitations. An arrhythmia is an irregular heartbeat that can cause
the heart to pump blood less eﬀectively. Patients with heart failure and/or
arrhythmias may also be at substantial risk for stroke and other complica-
tions (American Heart Association 2006). Treatment for heart failure in-
cludes ace-inhibitors or angiotensin II receptor blockers, beta-blockers,
and diuretics. Appropriate patients may also undergo valve replacement
surgery or other revascularization. Patients with arrhythmias often receive
pacemakers and occasionally receive implantable cardioverter deﬁbrilla-
tors along with antiarrhythmic drugs and blood thinners.
Other cardiovascular diseases, generally with smaller prevalence, in-
clude rheumatic heart disease, aneurysms, acute pulmonary heart disease,
other diseases of the endocardium, capillary diseases, and problems with
veins (e.g., varicose veins).
6.2 The Importance of Cardiovascular Disease 
for Reductions in Disability
Like every multidimensional concept, there is no perfect measure of dis-
ability. We follow the lead of most researchers in measuring disability as
the presence of impairments in Activities of Daily Living (ADLs) and In-
strumental Activities of Daily Living (IADLs). Our data source, the Na-
tional Long-Term Care Survey of 1984–1999 (NLTCS) includes informa-
tion on six ADL measures: eating, getting in or out of bed, walking around
inside, dressing, bathing, and getting to the toilet or using the toilet. Ques-
tions are also asked about eight IADL measures: doing light housework,
laundry, preparing meals, shopping for groceries, getting around outside,
managing money, taking medications, and making telephone calls.
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health and disability proﬁle population aged sixty-ﬁve and over. The ﬁrst
NLTCS survey wave was conducted in 1982 and subsequent surveys were
administered in 1984, 1989, 1994, and 1999. Each survey wave began with
a screener that collected information on whether the respondent reported
inability to conduct the six ADLs and eight IADLs without help (i.e., help
from another person or special equipment), and whether these limitations
had lasted or was expected to last at least three months. The screener also
collected demographic information on marital status, race, and age.
Respondents who reported inability to perform any ADLs or IADLs for
at least three months on the screener were asked to complete a detailed sur-
vey. Disability status was determined by responses to questions about use
of help and inability to conduct the ADLs and IADLs on the detailed sur-
vey. Sampling and weighting issues are described fully elsewhere (Manton,
Corder, and Stallard 1993; Manton, Corder, and Stallard 1997; Manton,
Stallard, and Corder 1997; Singer and Manton 1998; Manton and Gu
2001).
We obtained Medicare-linked data for all NLTCS participants, includ-
ing data on date of death from the denominator ﬁles. We used inpatient
claims for all analyses because Medicare claims ﬁles for Part B and other
nonhospital services were incomplete prior to 1991. We also obtained data
on zip code of residence at the most recent interview for all NLTCS survey
respondents.
Basic data on disability among the elderly population is shown in ﬁgure
6.1. For reasons that will become clear shortly, we report disability for the
population that is aged seventy and older in each of three years: 1989, 1994,
and 1999. The share of the elderly population that is disabled declined
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Fig. 6.1 Share of population 70  who are disabled
Note: Disability is deﬁned as any diﬃculty conducting Activities of Daily Living or Instru-
mental Activities of Daily Living without help.markedly in the 1990s. The cumulative decline was 6.3 percentage points,
or 2.1 percent per year.
To examine the role of cardiovascular disease in explaining this reduc-
tion in disability, we form a population sample likely aﬀected by the condi-
tion. We start by looking at the population aged seventy and older in the
1989, 1994, and 1999 surveys. For each of these cohorts, we group all hos-
pitalizations over the preceding ﬁve years into one of thirty-two categories
(the ﬁve-year look back is the reason for the restriction to people over sev-
enty). These categories were designed to pick up relatively homogenous
clinical conditions that would be predictive of disability. The set of thirty-
two categories is shown in table 6.1, along with the rate of disability for
people hospitalized with each condition from the 1989 survey cohort. The
relevant categories for cardiovascular disease are stroke, hypertension, is-
chemic heart disease, heart failure and arrhythmia, peripheral vascular
disease, and other circulatory diseases.2
Figure 6.2 reports the share of people with a hospitalization for any of
these conditions. Twenty-two percent of people were admitted to a hospi-
tal with some cardiovascular disease. Ischemic heart disease is the most
common admission. Stroke and heart failure are also common, as are
other circulatory diseases. Admissions for peripheral vascular disease and
hypertension are much less common.
A person who had a hospital admission for cardiovascular disease and
is disabled may or may not have been disabled because of that condition.
The NLTCS does not reliably determine the precise condition that leads to
each disability. We make two alternative assumptions about the probabil-
ity of being disabled by cardiovascular disease. The ﬁrst assumption, a less
restrictive assumption, labels someone as disabled from cardiovascular dis-
ease if he or she was admitted to a hospital with cardiovascular disease in
the previous ﬁve years. The more restrictive assumption subsets this group
to those for whom the most disabling condition was cardiovascular dis-
ease,3 where the list of conditions by disability status is reported in table
6.1. Thus, a person who had a stroke and hip fracture would be termed dis-
abled because of cardiovascular disease by the ﬁrst measure, but not by the
second measure. Fortunately, our results are very similar regardless of the
deﬁnition used.
Figure 6.3shows the probability of being disabled by cardiovascular dis-
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2. ICD-9 codes are as follows: stroke: 362.34, 430, 431, 432.9, 433–436; hypertension: 401–
402, 405, 437.0, 437.9; ischemic heart disease; 4.10–4.14, 429.5–429.7, excluding 414.11 and
414.19; heart failure and arrhythmia: 425, 427.1, 427.3–427.5, 428, 429.1, 429.3; peripheral
vascular disease: 440, 442, 443.0–443.1, 443.8–443.9, 444, 446, 447.0–447.5, 447.8–447.9,
451, 453.1; circulatory diseases: 391–400, 406–409, 414.11, 414.19, 415–424, 426, 427.2,
427.6, 427.8, 427.9, 429.2, 429.4, 429.8, 429.9, 432.1–432.8, 437.1–437.8, 439, 441, 443.2, 445,
447.6, 448–450, 452–453.0, 453.2–459, 786.5, V717.
3. Note even this more restrictive assumption may underestimate the importance of dis-
abling diseases, such as arthritis or dementia, that are not common causes of hospitalizations.ease. Using the less restrictive measure, the decline in disability is 1.4 per-
centage points, or 22 percent of the 6.3 percentage point total reduction in
disability. Using the more restrictive measure, the decline is 0.9 percentage
points, or 14 percent of the total decline. In each case, cardiovascular dis-
ease is a substantial share of the total decline.
As previously noted, the conclusion that cardiovascular disease is a sub-
stantial share of disability decline contradicts an earlier literature that sug-
gested that marginal survivors contribute to an increase in disability. If
more people survive strokes, the argument went, the share of the elderly
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Table 6.1 Most disabling conditions
Condition % disabled Rank
Chronic renal failure 88.9 1
Dementia and organic brain diseases 83.1 2
Paralysis, Parkinson’s, etc. 82.5 3
Hip and pelvic fracture 80.2 4
Acute renal failure and insuﬃciency 68.1 5
Other metabolic and immunity disorders 67.0 6
Other blood diseases 66.5 7
Respiratory failure and insuﬃciency 66.5 8
Anemia 65.9 9
Diabetes 64.1 10
Thyroid disorders 59.9 11
Stroke 59.5 12
Infectious diseases 59.2 13
Respiratory diseases 56.8 14
Depression 56.2 15
Peripheral vascular disease 55.4 16
Composite category 54.8 17
Musculoskeletal disorders 53.2 18
Heart failure and arrhythmia 51.5 19
Chronic obstructive pulmonary diseases and related diseases 51.0 20
Other mental disorders 49.9 21
Glaucoma and cataract 48.8 22
Hypertension 48.4 23
Gastrointestinal disease 45.2 24
Arthritis and arthropathy 45.0 25
Circulatory diseases 42.0 26
Colorectal and lung cancer 40.0 27
Back/neck pain 39.2 28
Ischemic heart disease 38.7 29
Genitourinary diseases 38.7 30
Other cancers 37.6 31
Breast and prostate cancer 28.9 32
Notes: Analyses conducted using 1989 cohort, and based on primary hospitalization diagno-
sis codes in the proceeding ﬁve years. Composite category includes hospitalizations for any
diagnoses other than the thirty-one speciﬁc categories above.with disabilities would rise. The ﬁnding of a reduction in disability sug-
gests, in contrast, two other hypotheses: either fewer people are suﬀering
cardiovascular disease events, or those who have always survived such
events are less disabled now than they were formerly (i.e., the incidence of
disability among cardiovascular disease patients is falling). These possible
eﬀects are demonstrated in equation (1):
(1) Pr (Disabled from CVD)   Pr (Had CVD Incident) 
  Pr (Survive | Had Event) 
  Pr (Disabled | Had Event, Survival)
The ﬁrst term on the right hand side is the incidence of events. The second
term is the survival rate, and the third term is the health eﬀect among sur-
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Fig. 6.2 Clinical conditions for people age 70  with cardiovascular disease
Note: The sample is NLTCS survey respondents with at least one CVD hospitalization in the
ﬁve years prior to the survey, for all three survey years pooled.
Fig. 6.3 Probability of being disabled because of cardiovascular disease
Note: Cross-sectional analyses based on hospitalizations in the ﬁve years prior to the survey.vivors. The change in disability rates is arithmetically related to the change
in one or more of these factors.4 The marginal survivors theory focuses on
the second term: the change in the probability of survival after an acute
event (i.e., as more patients survive acute events, the pool of people at risk
of disability expands). The other theories focus on the ﬁrst and third terms
(i.e., either reduced incidence of disease or better health among survivors).
Table 6.2 shows cardiovascular disease event probabilities, survival
rates, and conditional disability rates for each of our three time periods. To
measure the cardiovascular disease event rate, we consider the population
surveyed at the beginning of the ﬁve year interval, and look at events in
those ﬁve years. For example, the cardiovascular disease event rate for the
1989 cohort is the share of the population aged sixty-ﬁve and older in 1984
that had a cardiovascular disease hospital admission in the subsequent ﬁve
years.5
The ﬁrst row shows that the share of people who had a hospitalization
for cardiovascular disease was relatively constant over the time period, at
about 26 percent. This is somewhat surprising given the reduction in event
rates noted in other surveys such as the Framingham Heart Study
(Sytkowski et al. 1996) and the Minnesota Heart Survey (McGovern et al.
1996; McGovern et al. 2001). It may be that some of the admissions among
the later cohorts in our study were done explicitly to perform surgical op-
erations such as angioplasty or bypass surgery, and thus contribute to an
increased reporting of cardiovascular disease. However, another recent
U.S. study of subjects aged thirty-ﬁve to seventy-four reported little change
in the incidence of ﬁrst myocardial infarction between 1987 and 1994
(Rosamond et al. 1998). Alternatively, it may be that less severe cases of
these conditions are being diagnosed over time.6
In addition, the Framingham and Minnesota studies included patients
younger than sixty-ﬁve, and results from these studies may have been
driven by a decline in heart disease among the younger population. A
Finnish study of coronary heart disease between 1978–1980 and 2000–
2001 reported decreased prevalence of coronary heart disease among men
and women aged forty-ﬁve to sixty-four, no change in prevalence among
men and women aged sixty-ﬁve to seventy-four, and increased incidence
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4. There are covariance terms as well, but these are generally small.
5. Were the NLTCS a ﬁxed panel survey, the sample of people at the starting year (e.g.,
1984) would be only those for whom the disability status is known ﬁve years later plus those
who died in the interim. The NLTCS did not interview the entire sample every year, however,
so some people are lost to follow-up. To generate a nationally representative sample, we ana-
lyzed only those people whose health and mortality status were known at follow-up for each
survey year, and reweighted the sample weights to reﬂect the age-sex distribution of all re-
spondents to the 1999 survey.
6. Clinical trials published in 1996 showed that a blood test for troponin, a protein released
from damaged heart tissue, can be used to diagnose heart attacks. This likely led to greater di-
agnosis of smaller heart attacks and may also have led to increased hospitalizations, depend-
ing on how frequently these patients were previously admitted.among people aged seventy-ﬁve and over (Kattainen et al. 2004). Our re-
sults may reﬂect similar trends in age-related incidence of heart disease.
The second row of the table shows a signiﬁcant increase in the survival
rate to the next survey for people admitted to a hospital with cardiovascu-
lar disease. The survival rate increased by 4.3 percentage points, or about
7.5 percent. By itself, this would have led to an increase in disability from
cardiovascular disease. This eﬀect is overwhelmed, however, by the sub-
stantial reduction in disability among survivors, shown in the third row of
the table. The share of CVD survivors who are disabled fell from 48 percent
in 1989 to 39 percent in 1999, a 19 percent reduction. It is this massive re-
duction in event-speciﬁc disability that needs to be explained.
6.3 Medical Care and CVD-Related Disability
Before estimating formal statistical models to address the role of med-
ical care in reduced CVD-related disability, we consider a less structural
analysis of the role of medical care. Speciﬁcally, we look at how disability
changed in the period shortly after the cardiovascular disease event rela-
tive to the period several years later. If the reduction in disability followed
immediately after the cardiovascular event, it strongly suggests that med-
ical treatment of the acute event was the major factor responsible for the
reduction in disability. A future disability reduction might be attributable
to medical intervention, but other factors, such as better coping with limi-
tations due to improved environmental factors, could be important as well.
Figure 6.4 shows the change in disability rates for people whose cardio-
vascular disease event happened within six months of the survey, by type
of event. The rate of disability declined from 1984–1989 cohort to the
1994–1999 cohort for people with hospitalizations for ischemic heart dis-
ease, heart failure and arrhythmia, stroke, and other cardiovascular dis-
ease. For heart failure and arrhythmia patients as well as other cardio-
vascular diseases, there were increases in the disability rate from the 
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Table 6.2 Decomposing changes in cardiovascular disease disability
Cohort (%)
Change, 1984–89 
1984–1989 1989–1994 1994–1999 to 1994–99 (%)
Share with CVD event 26.5 29.0 26.3 –0.2
Share with an event who survive 57.2 58.4 61.5 4.3
Share of survivors who are disabled 47.6 43.7 39.4 –8.2
Source: Authors tabulations from the National Long-Term Care Survey.
Note: Data are based on respondents with a CVD hospitalization in between survey waves, and known
health status at the second survey. Weights were adjusted to the age and sex distribution of the 1999
NLTCS survey population, and account for unknown follow-up status at the second survey.1984–1989 to 1989–1994 cohorts that need further explanation.7 Overall,
though, it seems that medical advances could have some role in this decline
in disability between 1984–1989 and 1994–1999.
6.3.1 Empirical Methodology
To examine the role of medical technology changes in event-related re-
ductions in disability more formally, we estimate regression models for the
health of patients who have been admitted to a hospital with cardiovascu-
lar disease. Our sample is formed from each of the three cohorts. We select
people who were admitted to a hospital with cardiovascular disease in
1984–1989, 1989–1994, and 1994–1999. In each case, the sample includes
all people for whom we know health status at the beginning and end of the
ﬁve-year period. There are three possible health states at the end of each
period, that is, at the time of follow-up survey: dead, alive and nondisabled,
and alive and disabled. We denote these possible outcomes with the sub-
script k.
Consider for the moment a single measure of medical treatments, which
we wish to relate to the change in disability. For concreteness, assume that
the variable is the share of people in an area who receive a surgical proce-
Intensive Medical Care and Cardiovascular Disease Disability Reductions 201
7. For example, the average severity of heart failure hospitalizations may have increased
over time if physicians and patients were better able to manage heart failure in the outpatient
setting.
Fig. 6.4 Likelihood of reporting disability among respondents with speciﬁc cardio-
vascular disease events in the six months prior to surveydure that has been shown to be eﬀective in improving health for people
with that condition. The treatment rate for area jin time period tis denoted
Tj,t.We model the probability that person iin period twill be in health state
k using a multinomial logit formulation:
(2) Pr (health state k)i,j,t   
where Xi,t is a set of demographic and baseline health variables, and  ks are
the coeﬃcient of interest. Our control variables include: age/sex (ﬁve-year
age groups diﬀerentiated by gender); disability status at the baseline inter-
view; dummy variables for other cardiovascular disease hospitalizations
(with the exception of the all-CVD model, which does not require indica-
tor variables for other CVD diagnoses); a modiﬁed Charlson index (i.e.,
without cardiovascular disease diagnoses) (Deyo, Cherkin, and Ciol 1992);
marital status at the beginning of the ﬁve-year window (married, widowed,
divorced/separated, or missing marital status); race (white and nonwhite);
and zip code-level education and poverty measures (respondents’ educa-
tion and income were only available from the detailed interview).
One issue that comes up in any estimation involving an equation like (2)
is the issue of causality. If treatments are not randomly assigned, estimates
of   will be biased. We address this issue in several ways. The most impor-
tant is to use area-level variation in treatments, rather than individual-level
variation. Whether any individual receives a treatment is dependent on the
physician’s perception of that patient’s underlying health. If the underlying
severity of disease is relatively constant across areas and over time, how-
ever, variations in treatment at the area level will be good markers for ex-
ogenous changes in the use of medical care. As is standard in the literature
(O’Connor et al. 1999; Fisher et al. 2003a; Fisher et al. 2003b; Stukel, Lu-
cas, and Wennberg 2005), we group individuals into areas based on the
Hospital Referral Region (HRR) they live in. Hospital Referral Regions
are groups of zip codes where the bulk of patients go to the same set of hos-
pitals and include at least one hospital with a tertiary cardiovascular or
neurological surgical center. For example, the HRR for Chicago includes
zip codes 60601–60712; within this area, the vast majority of people who
are hospitalized get admitted to a hospital in that region.
6.3.2 Measures of Medical Treatment
We use several measures of medical care to predict disability. The ﬁrst
variable is the share of people who receive surgical interventions. To deﬁne
relevant procedures, we identify treatments for each speciﬁc diagnosis that
the medical literature has identiﬁed as being eﬃcacious (generally in re-
ducing mortality) for at least some subsets of patients with that diagnosis.
These procedures are detailed in table 6.3. For hypertension, there are no
exp (Xi,t k    kΤj,t    k cohortt)
              
(1   exp)(Σ Xi,t 1    1Τj,t    1 cohortt)
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the other conditions, of which the most common appropriate procedures
are “other operations on heart and pericardium” (CPT code 37), which in-
cludes PCI (angioplasty), heart replacement procedures and insertion of
pacemakers, and “incision, excision and occlusion of vessels” (CPT code
38), which includes endarterectomies. CABG procedures for ischemic
heart disease patients are coded under CPT code 36, “operations on ves-
sels of heart.”
Table 6.4 shows the average rate of procedure use over time across hos-
pital referral regions for all cardiovascular disease patients and by speciﬁc
conditions. In the 1984–1989 cohort, the average procedure rate was only
21 percent across regions. The average procedure rate was highest for other
circulatory diseases (30 percent), followed by ischemic heart disease (23
percent), stroke (13 percent) and heart failure and arrhythmia (11.3 per-
cent). By 1994–1999, the average procedure rate for all patients across all
regions increased to 34 percent. The average procedure rate for ischemic
heart disease patients jumped to 48 percent. Average procedure rates in-
creased to 43 percent for other circulatory diseases, 25 percent for stroke,
and 14.2 percent for heart failure and arrhythmia. These increases reﬂect
the greater belief among physicians about the eﬃcacy of therapy, and ad-
vances in the therapy itself.8
Our other measures of medical technology involve use of pharmaceuti-
cals for patients with acute myocardial infarction. As noted in the previous
section, these pharmaceuticals have been shown to improve survival, al-
though the overall eﬀect of pharmaceutical treatment on both improved
survival and disability in the elderly has not been well established. Ran-
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8. For example, catheters used in surgery have improved, and stents were developed for use
in angioplasty in the mid-1990s.
Table 6.3 Relevant procedures for cardiovascular disease admissions
Condition Appropriate procedures (CPT-4 Code)
Stroke Incision, excision, and occlusion of vessels (38)
Hypertension —
Ischemic heart disease Operations on vessels of heart (36)
Other operations on heart and pericardium (37)
Heart failure and arrhythmia Other operations on heart and pericardium (37)
Conversion of cardiac rhythm (99)
Peripheral vascular disease Incision, excision, and occlusion of vessels (38)
Operations on vessels (39)
Other procedures on musculoskeletal system (84)
Other circulatory diseases Operations on valves and septa of heart (35)
Other operations on heart and pericardium (37)
Incision, excision, and occlusion of vessels (38)domized studies comparing various treatments for ischemic heart disease
on functional status and quality of life reported improvements for most
outcome measures for both medical and surgical therapies (Rogers et al.
1990; Strauss et al. 1995; Hlatky et al. 1997; Pocock et al. 2000; Borkon et al.
2002; Pﬁsterer et al. 2003). However, most of these studies included pa-
tients under age sixty-ﬁve who may be more likely to improve than elderly
patients (Rogers et al. 1990; Strauss et al. 1995; Hlatky et al. 1997; Pocock
et al. 2000; Borkon et al. 2002). A recent trial comparing medical and sur-
gical management of elderly patients with coronary artery disease reported
improved quality of life at one year for both treatment arms (Pﬁsterer et al.
2003), suggesting that treatment likely reduces disability in the elderly pop-
ulation. However, no studies to date have estimated the eﬀect of increased
use of appropriate pharmaceutical treatments over time on disability rates
in the elderly population.
Pharmaceutical use is not captured in Medicare claims. Thus, we do not
have time series data on the use of pharmaceuticals by area. We do have a
snapshot of data on pharmaceutical use, taken from a survey of medical
records in the mid-1990s. The Cooperative Cardiovascular Project (CCP)
abstracted medical record data on 186,800 Medicare patients hospitalized
for an AMI between February 1994 and July 1995, including data on
appropriateness for and receipt of guideline-recommended treatments
(Marciniak et al. 1998).
Use among patients most suited for treatment ranged from 51 percent
for beta-blockers in the immediate postmyocardial infarction treatment to
76 percent for aspirin. Average utilization rates for the mid-1990s are
shown in table 6.4. Researchers at Dartmouth have calculated the average
use rate of each of these pharmaceuticals at the HRR level, which we em-
ploy in our analysis (O’Connor et al. 1999).
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Table 6.4 Average rates of procedures and pharmaceuticals
Measure 1984–1989 1989–1994 1994–1999
Share of people receiving relevant 
procedure, % (SD) 21.1 (0.4) 26.1 (0.5) 34.2 (0.6)
By speciﬁc conditions
Ischemic Heart Disease 22.6 (0.9) 33.2 (1.0) 47.9 (1.3)
Stroke 13.0 (0.8) 17.1 (0.9) 24.8 (1.0)
Heart Failure 11.3 (0.6) 11.9 (0.8) 14.2 (0.9)
Other Circulatory Diseases 29.7 (1.1) 32.5 (1.2) 43.0 (1.3)




Note: Based on respondents with a CVD hospitalization between survey waves. The proce-
dure ﬁgures are the averages across HRRs, consistent with the CCP data.While not known at the area level, use of these pharmaceuticals did in-
crease during our study time frame. Reported use of aspirin for heart at-
tack patients in 1985 and between 1998 and 2000 was 30 percent and 85
percent, respectively, and over the same time, use of beta-blockers was 
48 percent and 72 percent, thrombolytics was 9 percent and approximately 
80 percent, and ace-inhibitors was 0 percent and 71 percent, respectively
(Jencks et al. 2000; Heidenreich and McClellan 2001; Vaccarino et al.
2005). The change in ace-inhibitors use from this study was based only on
changes in the Worcester, Massachusetts area and may not reﬂect changes
in use nationally.
The lack of time series data on pharmaceutical use at the area level re-
quires us to modify our analyses. Equation (2) assumes that we have time-
varying data on procedures and pharmaceuticals. Since we can only assign
patients to true area levels for pharmacological treatments in 1994–1995,
we estimated a model with all CCP variables on the 1994–1999 cohort only.
We estimate a separate model using the panel data and time-varying pro-
cedures variables based on equation (2).
From our models, we estimate the likelihood of being disabled, dead,
alive, and nondisabled at follow-up if all respondents lived in HRRs that
provided relevant procedures and pharmaceuticals from the 10th to the
90th percentiles of care, holding all other covariates at their observed lev-
els. We further estimate how much of the change in disability and death
over time may be explained by increased use of appropriate treatments that
were signiﬁcantly associated with lower disability and death, based on av-
erage use of procedures during each cohort period and estimates from the
literature of average use in 1985 and 1999 (i.e., between 1998 and 2000). We
deﬁned appropriate treatments for these analyses as those treatments with
class IA recommendations from recent guidelines. These include the rele-
vant procedures for Ischemic Heart Disease (IHD) and heart failure as
well as all of the pharmacological treatments for IHD, reperfusion and as-
pirin for stroke, and beta-blockers and ace-inhibitors for heart failure and
arrhythmia (Braunwald et al. 2002; Antman et al. 2004; Hunt et al. 2005;
Adams et al. 2007). We did not estimate a separate model for other circu-
latory diseases, because this category includes multiple diagnoses and has
no guidelines.
6.3.3 Estimation Results
Table 6.5 shows demographic characteristics of our cohort by year of
baseline survey. The proportion of respondents disabled at baseline de-
clined over time, from 32 percent in 1984 to 25.9 percent in 1994. This 6
percentage point decline in disability at baseline is consistent with other
analyses using the NLTCS (Manton and Gu 2001). In addition, there was
a slight increase in the mean modiﬁed Charlson index score from 0.94 in
1984 to 1.07 in 1994.
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any of the CVD conditions, except for heart failure and arrhythmia pa-
tients who had slightly increased probability of disability over time (table
6.6). The share of patients alive and nondisabled at follow-up increased
over time for all CVD conditions, including heart failure and arrhythmia;
the increase ranged from 8 percent among circulatory disease patients to
32 percent for stroke patients.
Coeﬃcients and standard errors from our estimation results are shown
in tables 6.7–6.10for models with all CVD patients, ischemic heart disease,
stroke, and heart failure patients. Each table includes a panel data model
with covariates for baseline survey year and area-level relevant procedures
as well as a model on the 1994–1999 cohort with covariates for area-level
appropriate pharmaceutical use and relevant procedures, with the excep-
tion of the stroke table, which only includes the model on the 1994–1999
cohort.
All-CVD
Area-level use of relevant procedures was not signiﬁcantly associated
with lower disability or death in the model with panel data nor in the model
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Table 6.5 Demographic characteristics of CVD cohort, by year of baseline survey
1984 1989 1994
N   4,146 N   3,671 N   3,676
wN   6,403,326 wN   7,935,884 wN   7,723,454
Age groups, %
65–69 20.0 21.6 21.0
70–74 24.8 24.3 22.7
75–79 23.2 23.4 24.0
80–84 17.2 16.7 17.1
85  14.8 14.1 15.2
Male, % 45.0 45.7 45.4
Nonwhite, % 8.0 7.9 8.8
Marital status, %
Married 51.3 51.1 51.3
Widowed 39.6 37.8 36.7
Divorced, separated, or single 8.1 10.0 9.5
Unknown marital status 1.1 1.1 2.4
Disabled at baseline survey, % 32.2 30.0 25.9
Modiﬁed Charlson comorbidy 
indexa, mean (SD) 0.94 (0.02) 1.04 (0.02) 1.07 (0.02)
Note: Estimates adjusted to the age and sex distribution of the 1999 population of Medicare
beneﬁciaries.
aHospitalizations for cardiovascular disease events were excluded from the Charlson index.Table 6.6 Health outcomes at follow-up over time, by CVD condition
% change, 
1984–1989—
1984–1989 1989–1994 1994–1999 1994–1999
Disabled at follow-up, %
All CVD 26.1 25.3 24.0 –8.1
IHD 23.3 22.2 21.5 –8.0
Stroke 31.0 31.7 29.5 –4.8
Heart failure and arrhythmia 21.8 23.5 22.9 5.5
Other circulatory disease 28.6 30.2 26.0 –9.1
Dead at follow-up, %
All CVD 41.7 42.2 39.3 –5.8
IHD 39.2 36.8 32.2 –17.9
Stroke 47.4 46.0 42.1 –11.2
Heart failure and arrhythmia 57.0 55.0 51.3 –9.9
Other circulatory disease 31.0 33.2 30.3 –2.2
Alive and nondisabled at follow-up, %
All CVD 32.2 32.5 36.7 14.0
IHD 37.4 41.0 46.3 23.8
Stroke 21.6 22.4 28.4 31.6
Heart failure and arrhythmia 21.3 21.6 25.7 20.8
Other circulatory disease 40.4 36.6 43.7 8.1
Table 6.7 All CVD: Multinomial regression models for health status outcome ﬁve years after
baseline survey
Model 1: Panel data Model 2: 1994 cohort only
Coeﬃcients (SEs) Disability Death Disability Death
Relevant procedures –0.000 (0.004) –0.006 (0.003) –0.001 (0.005) –0.006 (0.005)
Beta-blockers — — –0.012 (0.006)∗∗ –0.017 (0.005)∗∗∗
Aspirin — — 0.002 (0.011) 0.001 (0.010)
Reperfusion — — –0.019 (0.007)∗∗∗ –0.006 (0.007)




P-value P < 0.0001 P < 0.0001
Note: Models also adjust for age and sex interactions, disability status at the baseline interview, marital
status, race (white versus other), Charlson comorbidity score, and zip code-level measures of education
and poverty.
∗∗∗ Signiﬁcant at or below the 1 percent level.
∗∗ Signiﬁcant at or below the 5 percent level.Table 6.8 Ischemic heart disease: Multinomial regression models for health status outcome ﬁve
years after baseline survey
Model 1: Panel data Model 2: 1994 cohort only
Coeﬃcients (SEs) Disability Death Disability Death
Relevant procedures –0.005 (0.004) –.013 (.003)∗∗∗ –0.007 (0.005) –0.013 (0.005)∗∗
Beta-blockers — — –0.020 (0.010)∗∗ –0.020 (0.008)∗∗
Aspirin — — –0.009 (0.018) –0.010 (0.018)
Reperfusion — — –0.014 (0.012) –0.010 (0.011)




P-value P < 0.0001 P < 0.0001
Note: Models also adjust for age and sex interactions, disability status at the baseline interview, marital
status, race (white versus other), zip code-level measures of education and poverty, Charlson comorbid-
ity score, and hospitalizations for stroke, hypertension, heart failure, peripheral vascular disease, and
circulatory diseases.
∗∗∗ Signiﬁcant at or below the 1 percent level.
∗∗ Signiﬁcant at or below the 5 percent level.
Table 6.9 Stroke: Multinomial regression models for health status outcome ﬁve
years after baseline survey
Model 2: 1994 cohort only
Coeﬃcients (SEs) Disability Death
Relevant procedures — —
Beta-blockers — —
Aspirin 0.009 (0.023) –0.019 (0.021)





P-value P < 0.0001
Note: Model also adjusts for age and sex interactions, disability status at the baseline inter-
view, marital status, race (white versus other), zip code-level measures of education and pov-
erty, Charlson comorbidity score, and hospitalizations for ischemic heart disease, hyperten-
sion, heart failure, peripheral vascular disease, and circulatory diseases.
∗∗ Signiﬁcant at or below the 5 percent level.on the 1994–1999 cohort, after adjusting for baseline survey year, demo-
graphics, and health characteristics. In the 1994–1999 cohort model, beta-
blockers were signiﬁcantly associated with lower disability and mortality,
and reperfusion was associated with signiﬁcantly lower disability. Ace-
inhibitors were signiﬁcantly associated with worse outcomes in this model,
including increased disability and death.
Predicted event rates by percentiles of beta-blocker and reperfusion use
for all CVD patients are shown in ﬁgure 6.5.We estimate that disability and
death at follow-up would decline 5 percent and 19 percent, respectively, if
all patients moved from areas providing beta-blockers at the 10th per-
centile level to areas providing beta-blockers at the 90th percentile level.
Based on average use in 1984 (48 percent) and 1999 (72 percent), we esti-
mate that increased use of beta-blockers may have led to a 12 percent de-
cline in mortality (from 39.2 percent to 34.5 percent) and a 3 percent 
decline in disability (from 23.7 percent to 22.9 percent). These declines in
mortality and disability associated with increased beta-blocker use repre-
sent approximately 194 percent and 38 percent of the observed declines in
mortality and disability, respectively, between 1984 and 1999.
The eﬀect of reperfusion on disability across the percentiles of care is
quite large. The probability of disability at follow-up declines approxi-
mately 22 percent from 27 percent to 21 percent if all patients moved from
10th percentile areas for reperfusion to 90th percentile areas. Based on av-
erage use over the study time frame, we estimate that increased use of reper-
fusion may have led to a 51.5 percent decline in disability, from 41.8 per-
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Table 6.10 Heart failure and arrhythmia: Multinomial regression models for health status
outcome ﬁve years after baseline survey
Model 1: Panel Data Model 2: 1994 cohort only
Coeﬃcients (SEs) Disability Death Disability Death
Relevant procedures –0.001 (0.006) 0.002 (0.005) –0.003 (0.010) 0.005 (0.008)
Beta-blockers — — –0.023 (0.009) ∗∗ –0.019 (0.008)∗∗
Aspirin — — — —
Reperfusion — — — —




P-value P < 0.0001 P < 0.0001
Note: Models also adjust for age and sex interactions, disability status at the baseline interview, marital
status, race (white versus other), zip code-level measures of education and poverty, Charlson comorbid-
ity score, and hospitalizations for stroke, hypertension, ischemic heart disease, peripheral vascular dis-
ease, and circulatory diseases.
∗∗Signiﬁcant at or below the 5 percent level.cent to 20.3 percent. The decline in disability associated with reperfusion
is substantially greater than the observed decline in disability. However, be-
cause of the substantial increase in the use of reperfusion over this time
frame, these calculations involve out-of-sample projections and should be
viewed cautiously.
Ischemic Heart Disease
In both the panel data model and the model on the 1994–1999 cohort,
relevant procedures were associated with signiﬁcantly lower mortality. The
coeﬃcient on the relevant procedures variable in both models was approx-
imately the same (–0.013), suggesting the eﬀect of the procedures on death
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Fig. 6.5 All CVD: Adjusted probability of death and disability at follow-up by per-
centiles of beta-blocker and reperfusion usemay not be confounded by inclusion or exclusion of the pharmacological
treatments in the two models. In the model on the 1994–1999 cohort, beta-
blockers were signiﬁcantly associated with lower disability and death.
Figure 6.6 shows predicted event rates based on percentiles of relevant
procedures and beta-blocker use. If all patients lived in 10th percentile 
areas (0 percent procedure use), approximately 40 percent would die by 
follow-up compared to only 28 percent if all patients lived in 90th per-
centile regions (70 percent procedure use). If all patients were treated at the
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Fig. 6.6 IHD: Adjusted probability of death and disability at follow-up by per-
centiles of invasive procedures and beta-blocker useaverage level in 1984 (23 percent) and in 1999 (48 percent), the percentage
dead at follow-up would fall from 35.4 percent to 31.1 percent, which ac-
counts for approximately 61 percent of the decline in IHD mortality over
time. For beta-blockers, the share disabled and dead at follow-up would
decline by approximately 23 percent and 20 percent, respectively, if all
patients moved from 10th percentile to 90th percentile treatment areas
(29.2 percent versus 70.8 percent). If all patients were treated at the aver-
age levels in 1984 (48 percent) and 1999 (72 percent), disability would de-
cline from 21.8 percent at the 1984 level to 18.6 percent at the 1994 level.
Mortality would also fall from 33.5 percent to 29.1 percent. These ﬁgures
represent more than 100 percent of the observed disability decline and 63
percent of the decline in mortality.
Stroke
In the 1994–1999 model with stroke patients, reperfusion was associated
with signiﬁcantly lower disability at follow-up. Predicted event rates for
stroke patients, based on percentiles of reperfusion use, are shown in ﬁg-
ure 6.7. Increasing reperfusion use from 10th to 90th percentile levels
would lower disability approximately 34 percent from 35 percent to 23 per-
cent. Based on the increase in average use from 1984 to 1999, reperfusion
explains more than 100 percent of the decline in disability among stroke
patients.
Heart Failure and Arrhythmia
In the panel data model, heart failure and arrhythmia patients were sig-
niﬁcantly less likely to die in 1994–1999 cohort compared to 1984–1989
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Fig. 6.7 Stroke: Adjusted probability of death and disability at follow-up by per-
centiles of reperfusion use(table 6.10). Relevant procedures were not associated with disability or
death in either the panel data model or the model on the 1994-1999 cohort.
Beta-blockers were associated with lower disability and death, and ace-
inhibitors were associated with increased mortality and disability. We esti-
mate that moving all patients from 10th percentile to 90th percentile levels
of beta-blocker treatment would lower disability by 21 percent and mor-
tality by 9 percent (ﬁg. 6.8). We also ﬁnd that increased use of beta-
blockers from average levels in 1984 to 1999 would have led to a decline in
disability among heart failure patients, in contrast to the observed increase
in disability. In addition, this would have led to a 6 percent decline in death
over time from 50.6 percent to 47.6 percent, and would explain approxi-
mately 53 percent of the observed decline in mortality.
6.4 Interpreting the Results
Use of eﬀective treatments contributed to the decline in disability and
death among cardiovascular disease patients. With the exception of ace-
inhibitors in the heart failure and arrhythmia and all-CVD models, in-
creased use of eﬀective treatments was associated with improved health
outcomes. In particular, increased use of beta-blockers explained more
than 100 percent of the decline in disability among IHD and heart failure
patients, as well as 63 percent to 53 percent of the decline in mortality over
time. Stroke patients beneﬁted from increased use of reperfusion between
1984 and 1999, which explained over 100 percent of the decline in disabil-
ity. Invasive procedures were important for IHD patients and explained
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Fig. 6.8 Heart failure and Arrhythmia: Adjusted probability of death and disabil-
ity at follow-up by percentiles of beta-blocker useapproximately 60 percent of the decline in mortality over the study time
frame. The role of beta-blockers in explaining more than 100 percent of the
decline in disability for IHD and heart failure patients as well as reperfu-
sion for disability among stroke patients may seem overstated. However,
adverse trends in risk factors for cardiovascular disease morbidity and
mortality not included in our models, such as diabetes and obesity, were 
increasing over this time frame (Cooper et al. 2000; Villareal et al. 2005;
Cowie et al. 2006). Our results suggest that the excess reduction in disabil-
ity attributable to improved treatments may be explained by increased risk
for morbidity in the elderly population over time.
Improved medical treatment after an acute cardiovascular event re-
sulted in improved survival and reductions in disability. It may also aﬀect
medical spending. While we cannot do a complete evaluation of the impact
of these changes, we can provide some information. We begin with the
change in quality-adjusted life expectancy. To consider how reductions in
disability in one year translate into long-term changes in quality-adjusted
life expectancy, we estimate regression models for future survival and dis-
ability status as a function of disability in a base year. For a cohort in year
t, we estimate linear probability models of the form:
(3) Pr (Alive in year t   k )i   Xi,t    Disabilityi,t   ei,t.
The coeﬃcient  indicates how changes in disability in year taﬀect long-
term health outcomes, and Xi,t is a set of demographic and health status
variables. The identifying assumption in equation (3) is that people who
are not disabled because of medical treatment are subsequently equivalent
in their health to those who never had an incident. This may or may not be
the case. If this is not true, and survivors of events are less healthy, condi-
tional on disability status, we will overstate the beneﬁts of reductions in dis-
ability. Thus, one should properly view these estimates as an upper bound
on the impact of medical interventions to reduce disability.
Figure 6.9 shows the survival rate by year, conditional on disability sta-
tus in the base survey year. We report the results for the ten years after the
survey for the 1989 cohort, and the ﬁve years after the survey for the 1994
cohort due to data limitations on long-term follow-up. Not surprisingly,
survival for the disabled is below that for the nondisabled by a large mar-
gin. The diﬀerence is about 20 percentage points, and remains at that level
throughout the decade. To forecast mortality beyond the ten-year obser-
vation window, we assume that the mortality hazard estimated in 1997–
1999 prevails in all subsequent years. Making this assumption, we estimate
that those not disabled in 1989 have an average life expectancy of 7.8 years
while those disabled in 1989 were expected to live only another 5.1 years on
average (table 6.11).
This calculation does not account for the diﬀerence in subsequent dis-
ability in the next decade. Table 6.12 shows the disability rate for the 1989
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hort in 1999. In each case, we condition disability status on being alive at
the end date. Seventy-nine percent of people who were disabled in 1989 and
still alive in 1994 were also disabled in 1994, compared to 31 percent of
those not disabled in 1989. This pattern repeats itself in 1999 and is true for
the 1994 cohort as well.
To estimate quality-adjusted life expectancy, we interpolate disability
rates between 1989 and 1994, and 1994 and 1999. In each case, we assume
that disability rates change at a common rate each year of the interval. We
Intensive Medical Care and Cardiovascular Disease Disability Reductions 215
Fig. 6.9 Survival by disability and year
Table 6.11 The persistence of disability status across surveys
Cohort Not disabled at baseline Disabled at baseline
1989 Cohort
Pr [Disabled in 1994] 31.4 79.1
Pr [Disabled in 1999] 36.9 72.1
1994 Cohort
Pr [Disabled in 1999] 25.2 83.9
Note: Disability frequencies are conditional on being alive at follow-up.
Table 6.12 Life expectancy by disability status
Measure Not disabled Disabled Diﬀerence
Life expectancy 7.8 5.1 2.7
Quality-adjusted life expectancy 6.7 3.0 3.7
Source: Details about the calculations are described in text.also extrapolate disability rates after 1999, using the annual change be-
tween 1994 and 1999. As a rough approximation, we assume that one year
in a disabled state is equivalent to 0.5 quality-adjusted life years.
As the second row of table 6.12 shows, quality-adjusted life expectancy
is lower in each case than is life expectancy, but the diﬀerence between the
disabled and nondisabled is similar to the unadjusted estimates. The in-
crease in quality-adjusted life expectancy associated with not being dis-
abled is 3.7 years.
The value of this improvement in life expectancy depends on the value
of a year of life. Following a substantial recent literature (Viscusi and Aldy
2003), we assume that a year of life in good health is worth $100,000 (in
1992 dollars). We also assume that future values are discounted at a 3 per-
cent real rate of interest. Using these assumptions, we estimate the value of
disability prevention to be $316,000.
These beneﬁts need to be weighed against the cost of reducing disability.
These costs have two parts. The ﬁrst is the initial treatment cost that led to
the reduction in disability. To measure these costs, we use data on hospi-
talization spending for the 1989 cohort in the year after the CVD admis-
sion.9 The one-year interval is relatively common in studying acute treat-
ment for cardiovascular disease (Cutler and McClellan 2001; Skinner,
Staiger, and Fisher 2006). The limitation to hospital costs is because only
those data are reliable prior to 1991. We inﬂated all costs to a common year
of 1992 using the implicit GDP Price Deﬂator (Economic Report of the
President 1997). We estimate that in the year after the CVD event, hospi-
tal spending averages $8,610 for patients who do not receive relevant pro-
cedures and $16,332 for patients receiving relevant procedures.
Although treatment costs are approximately twice as high for respon-
dents receiving appropriate treatments, these costs may be oﬀset by lower
yearly spending in subsequent years among survivors. A previous study of
1982 and 1984 NLTCS respondents found annual per capita spending by
Medicare for respondents without any ADL or IADL limitations was ap-
proximately $3,275, compared to $7,400 for respondents with at least four
ADL and ﬁve IADL impairments, and $13,100 for institutionalized re-
spondents. These data suggest that the costs of intensive medical treat-
ments that prevent or delay disability may be oﬀset by lower annual aver-
age spending among healthier beneﬁciaries.
More recent studies using the Medicare Current Beneﬁciary Survey
found similar lifetime spending between nondisabled and disabled seventy-
year-olds, but life expectancy was approximately 2.7 years longer among
the nondisabled (Lubitz et al. 2003). This provides further evidence that av-
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9. By deﬁnition, all participants in the 1989 cohort had at least one CVD admissions be-
tween 1984 and 1989. We averaged costs across all CVD hospitalizations for respondents with
multiple relevant hospitalizations.erage annual spending may be lower among the nondisabled relative to the
disabled. However, another recent study found spending on the nondis-
abled is growing faster than spending on the disabled (Chernew et al. 2005).
Whether increased spending on intensive medical care treatments, such as
those for cardiovascular disease, continues to increase life expectancy and
reduce average annual yearly spending among the nondisabled relative to
the disabled will require further investigation.
6.5 Conclusions
Examining disability associated with cardiovascular disease leads to sev-
eral important results. Reduced disability associated with cardiovascular
disease accounts for a signiﬁcant part of the total reduction in disability—
between 19 and 22 percent. The evidence suggests that improvements in
medical care, including both increased use of relevant procedures and
pharmaceuticals, led to a signiﬁcant part of this decline.
While precise data on the implications of reduced disability are lacking,
the possible impact of disability reductions is staggering. We estimate that
preventing disability after an acute event can add as much as 3.7 years of
quality-adjusted life expectancy, or perhaps $316,000 of value. The cost of
this change is much smaller. The initial treatment costs range from $8,610
to $16,332, depending on procedure use. Further, recent cost analyses re-
port that annual Medicare spending was lower for the nondisabled com-
pared to the disabled, which suggests that higher treatment costs may be
oﬀset by lower future spending among a more healthy population. By vir-
tually any measure, therefore, medical technology after acute cardiovascu-
lar episodes is worth the cost.
The major issue raised by our results is whether these conclusions extend
to other conditions. Disability reductions are complex, and will certainly
involve medical as well as nonmedical factors. Sorting these out for other
conditions is a high priority for future research.
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